- Home
- GALT vs SCLXW Comparison
GALT vs SCLXW Comparison
Compare GALT & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- SCLXW
- Stock Information
- Founded
- GALT 2000
- SCLXW N/A
- Country
- GALT United States
- SCLXW United States
- Employees
- GALT N/A
- SCLXW 113
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- GALT Health Care
- SCLXW Health Care
- Exchange
- GALT Nasdaq
- SCLXW Nasdaq
- Market Cap
- GALT 147.8M
- SCLXW N/A
- IPO Year
- GALT N/A
- SCLXW 2021
- Fundamental
- Price
- GALT $1.04
- SCLXW $0.22
- Analyst Decision
- GALT Strong Buy
- SCLXW
- Analyst Count
- GALT 1
- SCLXW 0
- Target Price
- GALT $11.00
- SCLXW N/A
- AVG Volume (30 Days)
- GALT 1.1M
- SCLXW N/A
- Earning Date
- GALT 11-13-2024
- SCLXW N/A
- Dividend Yield
- GALT N/A
- SCLXW N/A
- EPS Growth
- GALT N/A
- SCLXW N/A
- EPS
- GALT N/A
- SCLXW N/A
- Revenue
- GALT N/A
- SCLXW N/A
- Revenue This Year
- GALT N/A
- SCLXW N/A
- Revenue Next Year
- GALT N/A
- SCLXW N/A
- P/E Ratio
- GALT N/A
- SCLXW N/A
- Revenue Growth
- GALT N/A
- SCLXW N/A
- 52 Week Low
- GALT $0.73
- SCLXW N/A
- 52 Week High
- GALT $4.27
- SCLXW N/A
- Technical
- Relative Strength Index (RSI)
- GALT 20.80
- SCLXW N/A
- Support Level
- GALT $1.80
- SCLXW N/A
- Resistance Level
- GALT $2.36
- SCLXW N/A
- Average True Range (ATR)
- GALT 0.27
- SCLXW 0.00
- MACD
- GALT -0.08
- SCLXW 0.00
- Stochastic Oscillator
- GALT 15.07
- SCLXW 0.00
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.